Crinetics Pharmaceuticals (CRNX) News Today

Envestnet Asset Management Inc. lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51

Dimensional Fund Advisors LP lowered its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 14.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 546,759 shares

Marshall Wace LLP bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm bought 141,204 shares of the company's stock, valued at approximately $6,325,000. Marshall Wace LLP owned approxim

Novo Holdings A S lowered its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,000,000 shares of the company's stock after

Driehaus Capital Management LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 17.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,112,173 shares of the comp

JMP Securities restated a "market outperform" rating and set a $80.00 price target on shares of Crinetics Pharmaceuticals in a research note on Friday.

Maplelane Capital LLC acquired a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 160,000 shares of the company's

Point72 Asset Management L.P. lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 43.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,780,856 shares of the company's stock after selling 2,168,630 share

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the co

First Light Asset Management LLC cut its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 29.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,200,508 shares of the com

Integral Health Asset Management LLC raised its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 400,000 shares of the company's sto

Resolute Capital Asset Partners LLC raised its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 50.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 30,000 shares of the compa

Cantor Fitzgerald restated an "overweight" rating and issued a $90.00 target price on shares of Crinetics Pharmaceuticals in a report on Monday.

Victory Capital Management Inc. cut its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 11.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 226,687 shares of the company's sto

First Turn Management LLC purchased a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 369,302 shares of the company's stock, valued at appro

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Stephen F. Betz sold 1,035 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $51.50, for a total transaction of $53,302.50. Following the completion of the sale, the insider now owns 68,576 shares of the company's stock, valued at $3,531,664. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Nicholas Investment Partners LP acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 53,012 shares of the company's stock, valued at approximately $2,374

TD Asset Management Inc cut its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 12.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 204,998 shares of the company's stock after sell

Bank of New York Mellon Corp raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 30.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 386,450 shares of the company's stock after purcha

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 6,470,000 shares, an increase of 5.7% from the July 31st total of 6,120,000 shares. Based on an average trading volume of 809,300 shares, the days-to-cover ratio is presently 8.0 days.

Lisanti Capital Growth LLC grew its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 20.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 83,380 shares of the company's stock after buying an additional 1

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eleven have given a buy

Legato Capital Management LLC increased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 92.5% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,015 shares of the company's stock after purchasing an additi

Calamos Advisors LLC increased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 46.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,336 shares of the company's stock after purchasing an additional 13,336 shares dur

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 6,120,000 shares, a decline of 7.0% from the July 15th total of 6,580,000 shares. Based on an average daily trading volume, of 930,400 shares, the short-interest ratio is currently 6.6 days.

SG Americas Securities LLC boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 1,224.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 79,051 shares of the company's stock after purchasin

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.08). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.47 million. During the same period in the prior year, the business posted ($0.94) earnings per share. The company's revenue was down 59.6% on a year-over-year basis.

HC Wainwright boosted their price target on shares of Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the stock a "buy" rating in a research report on Friday.